Fujifilm corporation (20240099974). TREATMENT AGENT simplified abstract
Contents
- 1 TREATMENT AGENT
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 TREATMENT AGENT - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Unanswered Questions
- 1.11 Original Abstract Submitted
TREATMENT AGENT
Organization Name
Inventor(s)
Susumu Shimoyama of Cambridge MA (US)
Mikinaga Mori of Ashigarakami-gun (JP)
TREATMENT AGENT - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240099974 titled 'TREATMENT AGENT
Simplified Explanation
The present invention provides a treatment agent for Merkel cell cancer, consisting of a liposome containing topotecan, a modified lipid, dihydrosphingomyelin, cholesterol, and an inner water phase with an ammonium salt.
- Liposome-based treatment agent for Merkel cell cancer
- Liposome contains topotecan, a chemotherapy drug
- Lipid in the liposome is modified with polyethylene glycol, dihydrosphingomyelin, and cholesterol
- Inner water phase contains an ammonium salt
Potential Applications
The technology can be applied in the field of oncology for the treatment of Merkel cell cancer. It may also have potential applications in liposomal drug delivery systems for other types of cancer.
Problems Solved
This technology addresses the need for effective treatment options for Merkel cell cancer, a rare and aggressive form of skin cancer. By encapsulating topotecan in a liposome, the treatment agent may improve drug delivery and efficacy while reducing side effects.
Benefits
The liposome-based treatment agent offers targeted delivery of topotecan to cancer cells, potentially enhancing the drug's therapeutic effects. The use of a modified lipid with polyethylene glycol can improve the stability and circulation time of the liposome in the body.
Potential Commercial Applications
"Enhancing Cancer Treatment with Liposomal Topotecan: Potential Commercial Applications"
Possible Prior Art
There may be prior art related to liposomal drug delivery systems for cancer treatment, as well as research on the use of topotecan in oncology. However, the specific combination of components in the liposome for Merkel cell cancer treatment may be novel.
Unanswered Questions
What are the potential side effects of this treatment agent for Merkel cell cancer?
Further research and clinical trials are needed to determine the safety profile and potential side effects of the liposome-based treatment agent.
How does the efficacy of this treatment compare to traditional chemotherapy for Merkel cell cancer?
Comparative studies with standard chemotherapy regimens are necessary to evaluate the efficacy of the liposome-based treatment agent in treating Merkel cell cancer.
Original Abstract Submitted
an object of the present invention is to provide a treatment agent for merkel cell cancer. according to the present invention, there is provided a treatment agent for merkel cell cancer, having a liposome which has an inner water phase and having an aqueous solution which is an outer water phase and disperses the liposome, in which the liposome encompasses topotecan or a salt thereof, a lipid constituting the liposome contains a lipid modified with polyethylene glycol, dihydrosphingomyelin, and cholesterol, and the inner water phase contains an ammonium salt.
